Financial Comparison: Ascendis Pharma A/S (NASDAQ:ASND) versus Avalo Therapeutics (NASDAQ:AVTX)

Avalo Therapeutics (NASDAQ:AVTX) and Ascendis Pharma A/S (NASDAQ:ASND) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings and target prices for Avalo Therapeutics and Ascendis Pharma A/S, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalo Therapeutics	1	2	11	0	2.71
Ascendis Pharma A/S	0	2	19	0	2.90

Avalo Therapeutics presently has a consensus price target of $37.00, indicating a potential upside of 448.15%. Ascendis Pharma A/S has a consensus price target of $305.95, indicating a potential upside of 24.45%. Given Avalo Therapeutics’ higher probable upside, equities analysts plainly believe Avalo Therapeutics is more favorable than Ascendis Pharma A/S.

Valuation & Earnings

This table compares Avalo Therapeutics and Ascendis Pharma A/S”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalo Therapeutics	$59,000.00	6,135.64	-$234.36 million	($4.37)	-1.54
Ascendis Pharma A/S	N/A	N/A	N/A	$12.89	19.07

Ascendis Pharma A/S has lower revenue, but higher earnings than Avalo Therapeutics. Avalo Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Avalo Therapeutics and Ascendis Pharma A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Avalo Therapeutics	N/A	N/A	N/A
Ascendis Pharma A/S	N/A	N/A	N/A

Institutional & Insider Ownership

87.1% of Avalo Therapeutics shares are owned by institutional investors. 4.5% of Avalo Therapeutics shares are owned by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Ascendis Pharma A/S beats Avalo Therapeutics on 5 of the 8 factors compared between the two stocks.

About Avalo Therapeutics

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.